MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
underwritten public...
$269,834K
Proceeds from exercise of
stock options
$636K
Net cash provided by
financing activities
$270,533K
Net (decrease)
increase in cash, cash...
$196,292K
Canceled cashflow
$74,241K
Maturities of short-term
investments
$44,978K
Stock-based compensation
expense
$4,735K
Prepaid expenses and
other current assets
-$2,534K
Accrued expenses and
other current...
$1,696K
Non-cash lease expense
$567K
Depreciation and
amortization
$256K
Net (accretion) and
amortization of investments...
-$204K
Operating lease
liabilities
-$9K
Net cash used in
investing activities
-$56,776K
Net cash used in
operating activities
-$17,465K
Canceled cashflow
$44,978K
Canceled cashflow
$10,001K
Purchases of short-term
investments
$101,620K
Net loss
-$26,925K
Purchases of property and
equipment
$134K
Other assets
$362K
Accounts payable
-$179K
Back
Back
Cash Flow
source: myfinsight.com
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)